Please login to the form below

SGLT2 inhibitor

This page shows the latest SGLT2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

AZ’s Farxiga cuts risk of death in chronic kidney disease

The results were consistent in patients both with and without type 2 diabetes, opening up the potential market for the SGLT2 inhibitor if it wins approval in this indication. ... The results from this study are not likely to be available until 2022,

Latest news

Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial

The EMPEROR-Reduced trial evaluated SGLT2 inhibitor Jardiance (empagliflozin) in patients with heart failure with reduced ejection fraction (HFrEF). ... This includes AstraZeneca’s Farxiga (dapagliflozin), which became the first drug in the SGLT2
Merck, Bayer flesh out vericiguat heart failure data at ACC

Some outstanding questions include where vericiguat lies in relation to the SGLT2 inhibitors such as Boehringer Ingelheim/Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga/Forxiga (dapagliflozin), which are also ... Here too the SGLT2
FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

Formally rejects extended use of SGLT2 inhibitor. The US Food and Drug Administration (FDA) has formally rejected Eli Lilly and Boehringer Ingelheim’s bid to extend the use of their SGLT2 ... It also turned down Lexicon Pharma and Sanofi’s SGLT2
Trial of Amgen, Servier’s heart failure drug clears interim check

AstraZeneca is waiting for regulatory verdicts on its SGLT2 inhibitor Farxiga (dapagliflozin) as a treatment to reduce the risk of cardiovascular death or the worsening of heart failure in adults with ... Other drugs in the SGLT2 class – including
AZ says Brilinta hits the mark in new stroke trial

and its SGLT2 inhibitor Farxiga (dapagliflozin).

More from news
Approximately 2 fully matching, plus 85 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

checkpoint inhibitor Imfinzi such as the POSEIDON trial in first-line NSCLC, are key newsflow events this year. ... Diabetes therapy Farxiga (dapagliflozin) has the potential to go where no other drug in the SGLT2 inhibitor class has gone before as it
China: AstraZeneca’s new engine for growth and innovation

One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
Medius Deal Watch table for March 2015

Company acquisition. Marketed BTK inhibitor for haematological cancers pipeline incl. 3 products in clinic. ... 165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.
Interview: Christopher Boulton, AstraZeneca

Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The deal gives
Pharma deals during April 2013

The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... Clearly the pressure is on, the announcement coming only a

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Pfizer appoints diabetes expert Morris Birnbaum

Pfizer's interests in the area include a collaboration with Merck &Co on the sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin to treat diabetes.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Graphite Digital

Graphite is a digital agency which partners with globally respected healthcare organisations to create powerful digital experiences....

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....